| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2024―Aug―15 |
Are protein-ligand docking programs good enough to predict experimental poses of noncovalent ligands bound to the SARS-CoV-2 main protease? |
Ariadna Llop-Peiró, Guillem Macip, Santiago Garcia-Vallvé, Gerard Pujadas |
| 2 |
[GO] |
2024―Aug―02 |
An overview of the development of pharmacotherapeutics targeting SARS-CoV-2 |
Tom Lucaj, Ian Hay, Amirreza Samarbakhsh, Mel Bedi, Arun K. Iyer, Navnath S. Gavande |
| 3 |
[GO] |
2024―May―17 |
Targeting furin, a cellular proprotein convertase, for COVID-19 prevention and therapeutics |
Xia Jiang, Dabing Li, Mazaher Maghsoudloo, Xinghai Zhang, Wenzhe Ma, Junjiang Fu |
| 4 |
[GO] |
2023―Nov―28 |
Targeted degrader technologies as prospective SARS-CoV-2 therapies |
Rabia Khurshid, Joseph M. Schulz, Jiaming Hu, Timothy S. Snowden, Robert C. Reynolds, Stephan C. Schürer |
| 5 |
[GO] |
2023―Nov―16 |
Targeting SARS-CoV-2 nonstructural protein 3: function, structure, inhibition, and perspective in drug discovery |
Xin Li, Yongcheng Song |
| 6 |
[GO] |
2023―Sep―01 |
Deadly interactions: synergistic manipulations of concurrent pathogen infections potentially enabling future pandemics |
Kevin Roe |
| 7 |
[GO] |
2023―Jul―28 |
Analyzing 3D structures of the SARS-CoV-2 main protease reveals structural features of ligand binding for COVID-19 drug discovery |
Liang Xu, Ru Chen, Jie Liu, Tucker A Patterson, Huixiao Hong |
| 8 |
[GO] |
2023―Jul―22 |
Learning from COVID-19: How drug hunters can prepare for the next pandemic |
Ana C. Puhl, Thomas Lane, Sean Ekins |
| 9 |
[GO] |
2023―Jun―12 |
Harnessing aptamers against COVID-19: a therapeutic strategy |
Ali Mahmoudi, Seyedeh Hoda Alavizadeh, Seyedeh Atefeh Hosseini, Pouria Meidany, Maham Doagooyan, Yasaman Abolhasani, et al. (+5) Zakieh Saadat, Fatemeh Amani, Prashant Kesharwani, Fatemeh Gheybi, Amirhossein Sahebkar |
| 10 |
[GO] |
2023―Apr―05 |
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease |
Thales Kronenberger, Stefan A. Laufer, Thanigaimalai Pillaiyar |
| 11 |
[GO] |
2022―Sep―06 |
COVID-19 and fibrosis: mechanisms, clinical relevance, and future perspectives |
Mohd Aslam Saifi, Sapana Bansod, Chandraiah Godugu |
| 12 |
[GO] |
2022―Aug―19 |
The current status of COVID-19 vaccines. a scoping review |
Manuel Rueda-Fernández, Lucía Melguizo-Rodríguez, Víctor J. Costela-Ruiz, Anabel González-Acedo, Javier Ramos-Torrecillas, Rebeca Illescas-Montes |
| 13 |
[GO] |
2022―Jul―28 |
Nanosponges: an overlooked promising strategy to combat SARS-CoV-2 |
Ebrahim Mostafavi, Siavash Iravani, Rajender S. Varma |
| 14 |
[GO] |
2022―Jul―26 |
Impact of COVID-19 on male urogenital health: success of vaccines |
Kutay Kucukyildiz, Didem Yilmaz-Oral, Damla Turkcan, Cetin Volkan Oztekin, Serap Gur |
| 15 |
[GO] |
2022―Jul―04 |
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein |
Saroj Verma, Vaishali M. Patil, Manish K. Gupta |
| 16 |
[GO] |
2022―Apr―06 |
Repurposing drugs as COVID-19 therapies: a toxicity evaluation |
Deborah K. Ngan, Tuan Xu, Menghang Xia, Wei Zheng, Ruili Huang |
| 17 |
[GO] |
2022―Feb―19 |
Efficacy of repurposed antiviral drugs: lessons from COVID-19 |
Miguel Angel Martinez |
| 18 |
[GO] |
2022―Feb―10 |
Drug repurposing against SARS-CoV-2 using computational approaches |
Sumit Kumar, Svitlana Kovalenko, Shakshi Bhardwaj, Aaftaab Sethi, Nikolay Yu. Gorobets, Sergey M. Desenko, Brijesh Rathi |
| 19 |
[GO] |
2021―Dec―23 |
Organoid and microfluidics-based platforms for drug screening in COVID-19 |
Roya Ramezankhani, Roya Solhi, Yoke Chin Chai, Massoud Vosough, Catherine Verfaillie |
| 20 |
[GO] |
2021―Dec―23 |
Applications of density functional theory in COVID-19 drug modeling |
Naike Ye, Zekai Yang, Yuchen Liu |
| 21 |
[GO] |
2021―Dec―11 |
Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs |
Rosemarie Bernabe, Cristina Torres, Grace Wangge, Edlyn Jimenez, Juntra Karbwang |
| 22 |
[GO] |
2021―Nov―08 |
The PI3K/Akt/mTOR pathway: a potential pharmacological target in COVID-19 |
Maria Sofia Basile, Eugenio Cavalli, James McCubrey, Jorge Hernández-Bello, José Francisco Muñoz-Valle, Paolo Fagone, Ferdinando Nicoletti |
| 23 |
[GO] |
2021―Oct―29 |
Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling |
Gajjela Bharath Kumar, Ming-Ming Zhou |
| 24 |
[GO] |
2021―Oct―19 |
Integrating heterogeneous data to facilitate COVID-19 drug repurposing |
Lucía Prieto Santamaría, Marina Díaz Uzquiano, Esther Ugarte Carro, Nieves Ortiz-Roldán, Yuliana Pérez Gallardo, Alejandro Rodríguez-González |
| 25 |
[GO] |
2021―Jul―30 |
Advances in the computational landscape for repurposed drugs against COVID-19 |
Illya Aronskyy, Yosef Masoudi-Sobhanzadeh, Antonio Cappuccio, Elena Zaslavsky |
| 26 |
[GO] |
2021―Jul―29 |
Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management |
Vivek P. Chavda, Lalitkumar K. Vora, Anjali K. Pandya, Vandana B. Patravale |
| 27 |
[GO] |
2021―Jul―28 |
Harnessing the power of microphysiological systems for COVID-19 research |
Nicole Kleinstreuer, Anthony Holmes |
| 28 |
[GO] |
2021―Jun―18 |
Recent progress on rapid SARS-CoV-2/COVID-19 detection by CRISPR-Cas13-based platforms |
Guillermo Aquino-Jarquin |
| 29 |
[GO] |
2021―May―25 |
High-throughput screening assays for SARS-CoV-2 drug development: current status and future directions |
Tuan Xu, Wei Zheng, Ruili Huang |
| 30 |
[GO] |
2021―Apr―29 |
Revamping the Ever-changing Landscape of Drug Development Processes in the Midst of COVID-19 Pandemic |
Charles Oo, Barbara Ameer |
| 31 |
[GO] |
2021―Apr―21 |
Web resources facilitate drug discovery in treatment of COVID-19 |
Long-Can Mei, Yin Jin, Zheng Wang, Ge-Fei Hao, Guang-Fu Yang |
| 32 |
[GO] |
2021―Apr―21 |
The impact of COVID-19 on the cell and gene therapies industry: disruptions, opportunities, and future prospects |
Tingting Qiu, Yitong Wang, Shuyao Liang, Ru Han, Mondher Toumi |
| 33 |
[GO] |
2021―Apr―16 |
The fight against COVID-19: striking a balance in the renin-angiotensin system |
Alexis Q. Dean, William P. Bozza, Julianne D. Twomey, Shen Luo, Ancy Nalli, Baolin Zhang |
| 34 |
[GO] |
2021―Mar―26 |
Diabetes, inflammation, and the adiponectin paradox: therapeutic targets in SARS-CoV-2 |
Gilbert Ho, Alysha Ali, Yoshiki Takamatsu, Ryoko Wada, Eliezer Masliah, Makoto Hashimoto |
| 35 |
[GO] |
2021―Feb―21 |
Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition? |
Mary EW Collier, Shaowei Zhang, Nigel S Scrutton, Flaviano Giorgini |
| 36 |
[GO] |
2021―Feb―18 |
Developing new drugs that activate the protective arm of the renin angiotensin system as a potential treatment for respiratory failure in COVID-19 patients |
Mathilde Latil, Serge Camelo, Stanislas Veillet, René Lafont, Pierre J. Dilda |
| 37 |
[GO] |
2021―Jan―23 |
SARS-CoV-2-mediated hyperferritinemia and cardiac arrest: preliminary insights |
Prakash VasanthiDharmalingam, Vengadeshprabhu Karuppagounder, Kenichi Watanabe, Harry Karmouty-Quintana, Suresh S. Palaniyandi, Ashrith Guha, Rajarajan A. Thandavarayan |
| 38 |
[GO] |
2021―Jan―22 |
Drugs acting on the renin-angiotensin system and SARS-CoV-2 |
A. Vitiello, C. Pelliccia, Francesco Ferrara |
| 39 |
[GO] |
2021―Jan―14 |
Modelling the World - can deliberately infecting healthy volunteers really tell us much about what happens outside the clinic during an epidemic or pandemic? |
Adrian Wildfire |
| 40 |
[GO] |
2020―Dec―09 |
Potential SARS-CoV-2 main protease inhibitors |
Riddhidev Banerjee, Lalith Perera, L.M. Viranga Tillekeratne |
| 41 |
[GO] |
2020―Nov―27 |
Expanded Access Programs, compassionate drug Use, and Emergency Use Authorizations during the COVID-19 pandemic |
John G. Rizk, Donald N. Forthal, Kamyar Kalantar-Zadeh, Mandeep R. Mehra, Carl J. Lavie, Youssef Rizk, et al. (+2) JoAnn P. Pfeiffer, John C. Lewin |
| 42 |
[GO] |
2020―Oct―27 |
Union is strength: antiviral and anti-inflammatory drugs for COVID-19 |
J. Jesús Naveja, Abraham Madariaga-Mazón, Francisco Flores-Murrieta, Julio Granados-Montiel, Marco Maradiaga-Ceceña, Víctor Duarte Alaniz, et al. (+4) Maricruz Maldonado-Rodriguez, Jazmín García-Morales, Juan Pablo Senosiain-Peláez, Karina Martínez-Mayorga |
| 43 |
[GO] |
2020―Oct―06 |
Virus-, host-, immune-based targets for COVID-19 therapy |
Wei Liu, Hai-Liang Zhu, Yongtao Duan |
| 44 |
[GO] |
2020―Sep―16 |
Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms |
Nitesh Sanghai, Geoffrey K. Tranmer |
| 45 |
[GO] |
2020―Sep―01 |
Could PROTACs Protect Us From COVID-19? |
Wilnelly Martinez-Ortiz, Ming-Ming Zhou |
| 46 |
[GO] |
2020―Aug―12 |
Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites |
Sally El Kantar, Bilal Nehmeh, Philippe Saad, Gabie Mitri, Celine Estephan, Mohamad Mroueh, et al. (+2) Elias Akoury, Robin I. Taleb |
| 47 |
[GO] |
2020―Aug―07 |
Global clinical trial mobilization for COVID-19: higher, faster, stronger |
Reed F. Beall, Aidan Hollis |
| 48 |
[GO] |
2020―Jul―04 |
Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges |
Raymond Chang, Wei-Zen Sun |
| 49 |
[GO] |
2020―Jun―25 |
Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders |
Bruno O. Villoutreix, Philippe H. Beaune, Ryad Tamouza, Rajogapal Krishnamoorthy, Marion Leboyer |
| 50 |
[GO] |
2020―Jun―24 |
Emerging vaccine delivery systems for COVID-19 |
Nigel Theobald |
| 51 |
[GO] |
2020―Jun―24 |
Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19 |
Rajendran J.C. Bose, Jason R. McCarthy |
| 52 |
[GO] |
2020―Jun―20 |
Current and future therapeutical approaches for COVID-19 |
Yongtao Duan, Yongfang Yao, Senthil Arun Kumar, Hai-Liang Zhu, Junbiao Chang |
| 53 |
[GO] |
2020―Jun―20 |
Discovering small-molecule therapeutics against SARS-CoV-2 |
Vaibhav Tiwari, Jacob C. Beer, Nehru Viji Sankaranarayanan, Michelle Swanson-Mungerson, Umesh R. Desai |
| 54 |
[GO] |
2020―Jun―18 |
COVID-19 and pneumonia: a role for the uPA/uPAR system |
Daniele D’Alonzo, Maria De Fenza, Vincenzo Pavone |
| 55 |
[GO] |
2020―May―13 |
Shotgun drug repurposing biotechnology to tackle epidemics and pandemics |
William Mangione, Zackary Falls, Thomas Melendy, Gaurav Chopra, Ram Samudrala |
| 56 |
[GO] |
2020―May―06 |
Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment |
Lorraine O’Driscoll |
| 57 |
[GO] |
2020―May―01 |
Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19 |
Ilaria D’Acquarica, Israel Agranat |
| 58 |
[GO] |
2020―Apr―19 |
Déjà vu: Stimulating open drug discovery for SARS-CoV-2 |
Sean Ekins, Melina Mottin, Paulo R.P.S. Ramos, Bruna K.P. Sousa, Bruno Junior Neves, Daniel H. Foil, et al. (+6) Kimberley M. Zorn, Rodolpho C. Braga, Megan Coffee, Christopher Southan, Ana C. Puhl, Carolina Horta Andrade |
| 59 |
[GO] |
2020―Apr―15 |
Boosting the arsenal against COVID-19 through computational drug repurposing |
Gennaro Ciliberto, Luca Cardone |
| 60 |
[GO] |
2020―Mar―18 |
Advance of promising targets and agents against 2019-nCoV in China |
Yongtao Duan, Hai-Liang Zhu, Chongchen Zhou |
| 61 |
[GO] |
2020―Jan―30 |
Recent discovery and development of inhibitors targeting coronaviruses |
Thanigaimalai Pillaiyar, Sangeetha Meenakshisundaram, Manoj Manickam |
